3,363 Shares in Novavax, Inc. (NASDAQ:NVAX) Bought by GF Fund Management CO. LTD.

GF Fund Management CO. LTD. bought a new position in Novavax, Inc. (NASDAQ:NVAX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 3,363 shares of the biopharmaceutical company’s stock, valued at approximately $27,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVAX. Sanofi purchased a new position in Novavax during the fourth quarter valued at approximately $55,319,000. Deep Track Capital LP purchased a new stake in Novavax in the 4th quarter worth $16,080,000. BNP Paribas Financial Markets increased its holdings in Novavax by 289.0% in the 4th quarter. BNP Paribas Financial Markets now owns 556,832 shares of the biopharmaceutical company’s stock worth $4,477,000 after acquiring an additional 413,676 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Novavax during the 4th quarter worth $2,761,000. Finally, ExodusPoint Capital Management LP acquired a new stake in Novavax during the 4th quarter worth $2,687,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on NVAX shares. B. Riley reaffirmed a “buy” rating on shares of Novavax in a research note on Monday, May 19th. TD Cowen raised shares of Novavax to a “hold” rating in a research note on Thursday, February 27th. JPMorgan Chase & Co. lowered their target price on shares of Novavax from $9.00 to $7.00 and set an “underweight” rating on the stock in a research note on Friday, May 9th. Finally, BTIG Research began coverage on shares of Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $19.00.

Novavax Trading Up 1.8%

Shares of NVAX opened at $7.38 on Wednesday. The firm has a market cap of $1.20 billion, a P/E ratio of -3.27, a price-to-earnings-growth ratio of 2.85 and a beta of 3.21. Novavax, Inc. has a 12-month low of $5.01 and a 12-month high of $23.86. The company’s 50-day moving average price is $6.60 and its 200 day moving average price is $7.80.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $2.22. The company had revenue of $666.66 million during the quarter, compared to analysts’ expectations of $204.08 million. The firm’s quarterly revenue was up 610.3% on a year-over-year basis. During the same quarter last year, the firm posted ($1.05) earnings per share. Equities research analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.